daratumumab + hyaluronidase + pomalidomide + dexamethasone

This drug is a **combination therapy** comprising four active ingredients: daratumumab (an anti-CD38 monoclonal antibody), hyaluronidase (an enzyme facilitating subcutaneous delivery of daratumumab), pomalidomide (a third-generation immunomodulatory agent), and dexamethasone (a synthetic glucocorticoid corticosteroid). - **Daratumumab** targets CD38 on myeloma cells, inducing tumor cell death via immune-mediated mechanisms and direct cytotoxicity. - **Hyaluronidase** breaks down hyaluronic acid in tissues, permitting the subcutaneous administration of monoclonal antibodies like daratumumab, and increasing absorption rate. - **Pomalidomide** enhances immune system function, modulating cytokine production, and inducing apoptosis in myeloma cells through multiple mechanisms. - **Dexamethasone** reduces inflammation and suppresses immune responses, providing additional antitumor and supportive effects. This multi-agent regimen serves as a next-line therapy in adults with **relapsed or refractory multiple myeloma** who have failed previous lines (including lenalidomide and proteasome inhibitor), offering immunomodulatory, direct cytotoxic, and supportive anti-tumor effects[3][5].